ECM
BNTX icon

Endurant Capital Management’s BioNTech BNTX Stock Holding History

Endurant Capital Management’s Portfolio BNTX Stock Details BNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-21,664
Closed -$3.25M – 57
2022
Q4 		$3.25M Buy
+21,664
New +$3.33M 1.32% 19

Other funds holding BNTX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Flossbach Von Storch
Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AGA
Altrinsic Global Advisors Stamford, Connecticut $2.79B AUM 7.25% 1-Year Est. Return

Endurant Capital Management's BNTX Position: Q1 2023 in Review

Endurant Capital Management sold out of BioNTech (BNTX) in Q1 2023, closing a stake of 21,664 shares — an estimated $3.25M sold.

Endurant Capital Management first reported a position in BNTX in Q4 2022 and held it in 1 quarter. The position peaked at $3.25M in Q4 2022. 282 funds tracked by Wall St. Rank hold BNTX as of Q1 2023.

  • Endurant Capital Management reported no remaining BioNTech position as of Q1 2023 after selling out during the quarter.
  • Endurant Capital Management sold 21,664 BioNTech shares in Q1 2023, an estimated $3.25M.
  • Endurant Capital Management first reported a position in BioNTech in Q4 2022 and held it in 1 quarter.
  • Endurant Capital Management's BioNTech position peaked at $3.25M in Q4 2022.
  • 282 funds tracked by Wall St. Rank held BioNTech as of Q1 2023.

Based on Endurant Capital Management's 13F filing for Q1 2023, filed 15 May 2023.